New markers to predict the response to omalizumab in chronic spontaneous urticaria
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15589
Abstract: Omalizumab has high treatment efficacy in patients with chronic spontaneous urticaria (CSU) who do not respond to high doses of antihistamines. Systemic immune‐inflammation index (SII) and systemic inflammation response index (SIRI) were described as novel… read more here.
Keywords: sii siri; treatment; response; response omalizumab ... See more keywords
Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study
Sign Up to like & getrecommendations! Published in 2022 at "International Archives of Allergy and Immunology"
DOI: 10.1159/000526205
Abstract: Introduction: Chronic urticaria (CU) is a condition usually lasting longer than 6 weeks, with wheals and angioedema, sometimes both. Omalizumab is a recombinant humanized monoclonal IgG antibody developed against IgE. In some patients with CU,… read more here.
Keywords: omalizumab treatment; response omalizumab; count; treatment ... See more keywords